

Een uitzonderlijk goed jaar

Dominique-Jean Bouilliez

Referenties

1. Mayer IA, Balko JM, Kuba MG, et al. SU2C Phase Ib Study of pan-P13K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2- Metastatic Breast Cancer (MBC). SABCS 2011. Abstract#PD09-05.
2. Miller TW, Fox EM, Balko JM, et al. ER Downregulation with Fulvestrant in Combination with pan-P13K Inhibitor BKM120 Synergizes Against ER+/P13K-Mutant Breast Cancer Xenografts In Vivo. SABCS 2011. Abstract#S3-4.
3. Alban KS, Czerlanis C, Zlobin A, et al. Modulation of Cancer and Stem Cell Biomarkers by the Notch Inhibitor MK-0752 Added to Endocrine Therapy for Early Stage ER+ Breast Cancer. SABCS 2011. Abstract#S1-5.
4. O'Malley B. Nuclear Receptor Coactivators: Physiology and Disease. SABCS 2011. Abstract#BS2-2.
5. Gucalp A, Gupta G, Patil S, et al. Androgen Receptor (AR) Expression in a Cohort of Patients (pts) with Triple Negative Breast Cancer (TNBC). SABCS 2011. Abstract#P4-02-04.
6. Baselga J, Kim S-B, Im S-A, et al. A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Patients with Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA). SABCS 2011. Abstract#S5-5.
7. Cook RS, Balko JM, Rinehart C, et al. ErbB3 Expression Is Required for Maintenance of Normal and Transformed Luminal Breast Epithelial Cells. SABCS 2011. Abstract#S2-6.
8. Porter P. «Westernizing» women's risks? Breast cancer in lower-income countries 2008;358(3):213-6.
9. Anders CK, Fan C, Parker JS, et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 2011;29(1):e18-20.
10. Partridge A, Hughes M, Ottesen R, et al. Age and Survival in Women with Early Stage Breast Cancer: an Analysis Controlling for tumor Subtype. SABCS 2011. Abstract#P1-08-05.
11. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 2011;29(29):3885-91.
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
13. Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009;113(2):315-20.
14. Absiéf ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010;116(4):791-8.
15. Jones A. Fertility issues following breast cancer treatment. Adv Breast Cancer. FindArticles.com. 01 Feb, 2012.
16. Azim Jr HA, Santoro L, Russell-Edu W, Petheroudakis G, Pavlidis N, Peccatori FA. Prognosis of Pregnancy-Associated Breast Cancer: A Meta-Analysis Involving 39,415 Patients. SABCS 2011. Abstract#P4-11-03.
17. Henry NL, Banerjee M, Hayden J, et al. Predictors of Recovery of Ovarian Function during Aromatase Inhibitor (AI) Therapy. SABCS 2011. Abstract#PD04-01.
18. Park IH, Han H-S, Lee KS, et al. Resumption or Persistence of Menstruation after Cytotoxic Chemotherapy Is a Poor Prognostic Factor for Disease Free Survival in Premenopausal Patients with Early Breast Cancer. SABCS 2011. Abstract#P2-12-24.
19. Azim Jr HA, Metzger-Filho O, de Azambuja E, et al. Pregnancy during and Following Adjuvant Trastuzumab in Patients with HER2-Positive Breast Cancer: An Analysis from the HERA Trial (BIG 01-01). SABCS 2011. Abstract#P1-12-01.
20. Woodruff T. Oncofertility: Translation in the Multiple Dimensions. SABCS 2011. Abstract#E56-1.
21. Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 2010;28(12):2038-45.
22. Hind D, Wyld L, Beverley CB, Reed MW. Versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006;(1):CD004272.
23. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 2001;19(5):455-61.
24. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351(10):971-7.
25. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92(7):550-6.
26. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352(9132):930-42.
27. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29(25):3457-65.
28. Tahir M, Pretorius R, Robinson T, Walker R, Stotter A. Breast Cancer in Elderly Treatment Algorithm – A New Approach To Optimize the Management of Breast Cancer in Older Patients. SABCS 2011. Abstract#P5-23-03.
29. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339(6):357-63.
30. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20(15):3219-24.
31. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43(7):650-6.
32. Kristensen B, Ejlersten B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008;47(4):740-6.
33. Gnani M, Milneritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011;12(7):631-41.
34. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010;21(11):2188-94.
35. Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage III/IV breast cancer: The AZURE Trial (BIG 01/04). SABCS 2011. Abstract#S4-5.
36. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365(15):1396-405.
37. Gnani M, Milneritsch B, Luschin-Ebengreuth G, et al. Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor-Positive Early Breast Cancer. SABCS 2011. Abstract#S1-2.
38. Boer R, Bundred N, Eidtmann H, et al. Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST. SABCS 2011. Abstract#S1-3.
39. Coleman R, De Boer R, Eidtmann H, et al. Influence of Delayed Zoledronic Acid Initiation on Disease-Free Survival in Postmenopausal Women with Endocrine Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole: Exploratory Analyses from the ZO-FAST Trial. SABCS 2011. Abstract#P2-17-01.
40. Paterson AHG, Anderson SJ, Lembersky BC, et al. NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. SABCS 2011. Abstract#S2-3.
41. Möbus V, Diel IJ, Elling D, et al. GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis. SABCS 2011. Abstract#S2-4.
42. Mehta RS, Barlow WE, Albain KS, et al. A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226. SABCS 2011. Abstract#S1-1.
43. Bianchini G, Pusztai L, Iwamoto T, et al. Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome. SABCS 2011. Abstract#S1-7.
44. Dowsett M, Lopez-Knowles E, Sidhu K, et al. Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study. SABCS 2011. Abstract#S4-5.
45. Wagner LJ, Zhao F, Chapman J-AV, et al. Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/EI.Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole. SABCS 2011. Abstract#S6-2.
46. Goetz M, Hou X, Sunman V, et al. Endoxifen Exhibits Potent Anti-Tumor Activity and Regulates Different Genes Than Tamoxifen in an Aromatase Expressing MCF7 Model Resistant to Letrozole. SABCS 2011. Abstract#PD01-06.
47. von Minckwitz G, Blohmer JU, Costa S, et al. Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients – Results of the GeparTrio Trial. SABCS 2011. Abstract#S3-2.
48. Janni WJ, Harbeck N, Sommer H, et al. Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel vs. FEC 120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: Final Survival Analysis of the German ADEBAR Phase III Study. SABCS 2011. Abstract#PD07-01.
49. Watanabe T, Kuranami M, Inoue K, et al. Docetaxel Is Superior to Paclitaxel Given Every Three Weeks in Post Operative Patients with Node-Positive Breast Cancer: Results of the Final Analyses of the NSAS-BC (National Surgical Adjuvant Study of Breast Cancer) 02 Trial from Japan. SABCS 2011. Abstract#PD07-02.
50. Lam SW, de Groot SM, Honkoop AH, et al. Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG). SABCS 2011. Abstract#PD07-07.
51. Nitz U, Gluz O, Oberhoff C, et al. Adjuvant Chemotherapy with or without Darbepoetin alpha in Node-Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized VSG ARA 36 Trial. SABCS 2011. Abstract#PD07-06.
52. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011 Dec 7. [Epub ahead of print].
53. Hortobagyi GN, Piccart M, Rugo H, et al. Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. SABCS 2011. Abstract#S3-7.
54. Huober J, Hanusch C, Fasching PA, et al. Neoadjuvant Chemotherapy of Paclitaxel with or without Rad001: Results of the Non-Responder Part of the GEPARQUINTO Study (GBG 44). SABCS 2011. Abstract#S3-6.
55. Dabbs DJ, Bhargava R. Consistent High False Negative Rate of HER2 qRT-PCR of Oncotype DX® in Comparison to ASCO/CAP Recommended Combined IHC/FISH Method. SABCS 2011. Abstract#P1-07-20.
56. Viale G, Bogaerts J, van't Veer L, et al. High Concordance of Protein (by IHC), Gene (by FISH; H ER-2 Only) and Microarray Readout (by TargetPrint) of ER/PR/HER2: Results from the MINDACT Trial. SABCS 2011. Abstract#P1-07-06.
57. Richter S, Zandvakili A. Meta Analysis of Discordant HER2 Status in Matched Primary and Metastatic Breast Cancer. SABCS 2011. Abstract#PD05-05.
58. Crozier JA, Moreno-Aspitia A, Ballman KV, et al. Correlation between BMI and Clinical Outcome of Patients with Early Stage HER2+ Breast Cancer from the N9831 Clinical Trial. SABCS 2011. Abstract#P2-12-02.
59. Brockhoff G, Machleidt A, Priendl G, et al. HER4 Coexpression Is Associated with Improved Recurrence Free Survival in HER2-Positive, Herceptin Treated Patients. SABCS 2011. Abstract#P1-12-23.
60. Perez EA, Ballman KV, Reinholz MM, et al. Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831. SABCS 2011. Abstract#PD05-03.
61. Gianni L, Bianchini G, Kiermaier A, et al. Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2-Positive Breast Cancer (BC). SABCS 2011. Abstract#S5-1.
62. Alkhatieb AA, Connor J, Leitzel K, et al. Elevated Serum Ferritin Predicts Reduced Progression-Free and Overall Survival in Trastuzumab-Treated Metastatic Breast Cancer. SABCS 2011. Abstract#P5-14-11.
63. Minuti G, Duchnowska R, Jassem J, et al. MET and Hepatocyte Growth Factor (HGF) Increased Gene Copy Number Is Associated to Trastuzumab Failure in HER2 Positive Metastatic Breast Cancer (MBC). SABCS 2011. Abstract#P5-13-07.
64. Gullo G, Bettio D, Zardelli M, et al. Impact on Survival of the Level of HER2/neu Gene Amplification in Patients with HER2-Positive (HER2+) Advanced Breast Cancer (AdvBrCa) Treated with Trastuzumab (H). SABCS 2011. Abstract P1-12-22.
65. Loibl S, von Minckwitz G, Blohmer JU, et al. pCR as a Surrogate in HER2-Positive Patients Treated with Trastuzumab. SABCS 2011. Abstract#S5-4.
66. Ignatiadis M, Singhal SK, Desmedt C, et al. Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis. SABCS 2011. Abstract#PD03-10.
67. Amir E, Seruga B, Ocana A, Carlsson L, Bedard P. Pooled Analysis of Outcomes of T1a/bN0, HER2-Amplified Breast Cancer. SABCS 2011. Abstract#P2-12-07.
68. Rouanet P, Daures JP, Roger P, et al. HER2 Expression Is the Major Risk Factor for Recurrence in pT1a-bN0 Breast Cancer: A French Regional Population-Based Study of 671 Patients. SABCS 2011. Abstract#P2-12-16.
69. Meattini I, Livi L, Saieva C, et al. Prognostic Value of HER2 Positivity and Negative Hormonal Status in Patients with Small Tumor (< 1 cm) and Node-Negative Breast Cancer. SABCS 2011. Abstract#P2-12-14.
70. Pestalozzi B, Holmes E, Metzger O, et al. Trastuzumab Does Not Increase the Incidence of Central Nervous System (CNS) Relapses in HER2-Positive Early Breast Cancer: The HERA Trial Experience. SABCS 2011. Abstract#P4-17-01.
71. Schneeweiss A, Chia S, Hickish T, et al. Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA). SABCS 2011. Abstract#S5-6.
72. Goss P, Smith I, O'Shaughnessy J, et al. Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2-Overexpressing Breast Cancer. SABCS 2011. Abstract#S4-7.
73. Hurvitz S, et al. Trastuzumab emtansine (T-DM1) versus trastuzumab plus docetaxel in previously untreated HER2-positive metastatic breast cancer: ECCO-ESMO 2011; Abstract#S001.
74. Martin M, Bonnetterre J, Geyer Jr C, et al. A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer. SABCS2011. Abstract#S5-7.
75. Gianni L, Romieu G, Lichinitser M, et al. First Results of AVEREL, a Randomized Phase III Trial To Evaluate Bevacizumab (BEV) in Combination with Trastuzumab (H) + Docetaxel (DOC) as First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC). SABCS 2011. Abstract#S4-8.
76. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19.